Monopar Therapeutics (NASDAQ:MNPR) Sets New 12-Month High – Should You Buy?

Monopar Therapeutics Inc. (NASDAQ:MNPR) shares reached a new 52-week high during trading on Friday . The company traded as high as $116.69 and last traded at $114.70, with a volume of 160911 shares changing hands. The stock had previously closed at $114.66.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, July 12th. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Friday, July 17th. Zacks Research upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. Finally, HC Wainwright lifted their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $112.08.

Monopar Therapeutics Price Performance

The stock has a market capitalization of $760.99 million, a price-to-earnings ratio of -60.23 and a beta of 1.46. The business’s 50-day simple moving average is $84.55 and its two-hundred day simple moving average is $68.03.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.41. As a group, sell-side analysts expect that Monopar Therapeutics Inc. will post -2.82 EPS for the current year.

Institutional Trading of Monopar Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. acquired a new position in shares of Monopar Therapeutics during the first quarter worth about $673,000. Jane Street Group LLC acquired a new position in Monopar Therapeutics during the 1st quarter worth approximately $377,000. Geode Capital Management LLC boosted its holdings in Monopar Therapeutics by 99.7% in the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock worth $3,468,000 after acquiring an additional 48,379 shares during the period. JPMorgan Chase & Co. boosted its holdings in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares during the period. Finally, Rhumbline Advisers acquired a new stake in Monopar Therapeutics in the second quarter valued at approximately $209,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.